Fig. 2From: Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary careBurden of dyspnea among stable COPD patients by their index prescription. MRC-Medical Research Council dyspnea score, LAMA-long-acting muscarinic antagonist, LABA-long-acting beta2-agonistBack to article page